Design, chemical synthesis, and biological evaluation of novel triazolyl analogues of taranabant (MK-0364), a cannabinoid-1 receptor inverse agonist

[1]  Jinhwa Lee,et al.  Tetrazole-biarylpyrazole derivatives as cannabinoid CB1 receptor antagonists. , 2008, Bioorganic & medicinal chemistry letters.

[2]  W. Hagmann,et al.  Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist. , 2008, Journal of medicinal chemistry.

[3]  Jong Yup Kim,et al.  Convenient total synthesis of taranabant (MK-0364), a novel cannabinoid-1 receptor inverse agonist as an anti-obesity agent , 2007 .

[4]  L. Aronne,et al.  New Targets for Obesity Pharmacotherapy , 2007, Clinical pharmacology and therapeutics.

[5]  Rolee Pathak,et al.  Rimonabant: a novel selective cannabinoid-1 receptor antagonist for treatment of obesity. , 2007, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[6]  S. Majumdar,et al.  Drug treatments for obesity: orlistat, sibutramine, and rimonabant , 2007, The Lancet.

[7]  Yue Feng,et al.  Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity. , 2006, Journal of medicinal chemistry.

[8]  M. J. Bishop.  Approaches to antiobesity therapy. An introduction. , 2006, Journal of medicinal chemistry.

[9]  J. Antel,et al.  CB1 cannabinoid receptor antagonists for treatment of obesity and prevention of comorbid metabolic disorders. , 2006, Journal of medicinal chemistry.

[10]  G. Bray.  Obesity: the disease. , 2006, Journal of medicinal chemistry.

[11]  W. Finley,et al.  The prevalence and costs of obesity in the EU , 2005, The Proceedings of the Nutrition Society.

[12]  P. Shekelle,et al.  Meta-Analysis: Pharmacologic Treatment of Obesity , 2005, Annals of Internal Medicine.

[13]  C. Welch,et al.  Reactive resin facilitated preparation of an enantiopure fluorobicycloketone. , 2004, Organic & biomolecular chemistry.

[14]  T. Wadden,et al.  AGA technical review on obesity. , 2002, Gastroenterology.

[15]  F. Yokokawa,et al.  Total synthesis of the antiviral marine natural product (-)-hennoxazole A. , 2000, Organic letters.

[16]  Andrew Kopecky,et al.  Pseudoephedrine as a Practical Chiral Auxiliary for the Synthesis of Highly Enantiomerically Enriched Carboxylic Acids, Alcohols, Aldehydes, and Ketones , 1997 .

[17]  P. Reider.  Advances in AIDS Chemotherapy: The Asymmetric Synthesis of CRIXIVAN® , 1997, CHIMIA.

[18]  J. L. Gleason,et al.  Use of Pseudoephedrine as a Practical Chiral Auxiliary for Asymmetric Synthesis , 1994 .

[19]  A. Howlett,et al.  Determination and characterization of a cannabinoid receptor in rat brain. , 1988, Molecular pharmacology.

[20]  H. Matsumoto,et al.  Synthesis and oral antifungal activity of novel azolylpropanolones and related compounds. , 1987, Journal of medicinal chemistry.

[21]  S. Shimizu,et al.  Fluoride- or alkoxide-induced reaction of 1-[(trimethylsilyl)methyl]azoles with carbonyl compounds , 1986 .